Immunovant, Inc. IMVT NASDAQ

Immunovant, Inc. (IMVT) reported total assets of $776.22M and total liabilities of $68.78M for fiscal year 2025, resulting in total equity of $707.45M.

The company held $713.97M in cash and short-term investments. Total debt stood at $98K, with net debt of $-713.87M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 11.16, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 11.16 — balance sheet is strong
• MOAT (40/100) — Total assets $776.22M and equity $707.45M support the company's competitive scale
• VALUE (43/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 46/100 with 2/7 criteria passed.

KRTX

Karuna Therapeutics, Inc.

$329.83

+0.03%

MDGL

Madrigal Pharmaceuticals, Inc.

$524.99

-0.13%

BPMC

Blueprint Medicines Corporation

$129.46

+0.14%

ACLX

Arcellx, Inc.

$114.89

+0.02%

PTGX

Protagonist Therapeutics, Inc.

$104.72

+7.33%

ISEE

IVERIC bio, Inc.

$39.95

+0.38%

APLS

Apellis Pharmaceuticals, Inc.

$40.85

+0.02%

AKRO

Akero Therapeutics, Inc.

$54.65

+0.00%